文献速递甲状腺疾病

高危神经母细胞瘤幸存者的长期甲状腺毒性负担

Long-Term Thyroid Toxicity Burden in Children Who Received Treatment for High-Risk Neuroblastoma.
PubMed 文献 · Thyroid · 2026-02-24

这项单中心回顾性队列研究纳入45例高危神经母细胞瘤幸存者,中位随访10.6年,发现53%的患者出现长期甲状腺毒性,最常见为甲状腺功能减退。接受分子放疗、免疫治疗、串联清髓化疗或白消安的患者甲状腺毒性风险显著升高,且发生更早。

要点

  • 高危神经母细胞瘤幸存者长期甲状腺毒性发生率高,中位诊断后7.5年出现。
  • 分子放疗、免疫治疗、串联MAT及白消安暴露与甲状腺毒性风险显著相关。
  • 建议将内分泌长期随访延伸至成年期。

核心结论

  • 高危神经母细胞瘤幸存者因累积治疗负担面临显著的长期甲状腺毒性风险,即使治疗多年后仍可发生。

研究设计与样本

  • 回顾性单中心队列研究,纳入1996-2018年治疗且2023年6月1日存活、诊断后至少5年的45例高危神经母细胞瘤幸存者。

主要发现

  • 45例患者中24例(53%)报告长期甲状腺毒性,中位发生时间7.5年(范围1.2-18.2年,四分位距3-12年)。
  • 甲状腺功能减退最常见,占24例中的12例(50%)。
  • 10年无甲状腺毒性概率为62%(CI 44-75%)。
  • 接受分子放疗者10年无甲状腺毒性概率为0%,未接受者为72%(CI 53-85%),p<0.001。
  • 接受免疫治疗者10年无甲状腺毒性概率为30%(CI 6-59%),未接受者为78%(CI 65-90%),p=0.008。

关键数值与推荐

  • 接受串联MAT者10年无甲状腺毒性概率为37%(CI 12-64%),接受单次MAT者为71%(CI 49-85%),p=0.016。
  • 未接受白消安者10年无甲状腺毒性概率为86%(CI 39-98%),接受白消安者为55%(CI 35-71%),p=0.002。
  • 接受免疫治疗、131I-间碘苄胍治疗或白消安的患者甲状腺毒性发生显著更早(p=0.047)。

临床怎么用

  • 对高危神经母细胞瘤幸存者应进行长期甲状腺功能监测,并考虑将内分泌随访延续至成年期。

局限性

  • 回顾性单中心设计,样本量45例,可能限制结论外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multimodal treatment, including both conventional and myeloablative chemotherapy (MAT), radiotherapy, surgery, immunotherapy, and differentiating therapy, has increased survival for children affected by high-risk neuroblastoma (HRNB) at the potential cost of long-term endocrine morbidities. In this retrospective single-center study we investigate the long-term thyroid toxicity in neuroblastoma survivors. METHODS: This is a retrospective, single-center cohort study. HRNB survivors were followed in outpatient clinic with a scheduled long-term follow-up program; for this report, we considered patients alive on June 1, 2023 at least 5 years from diagnosis treated during 1996-2018 period. Data were obtained from a chart review and were evaluated as risk factors for long-term toxicity occurrence. RESULTS: Forty-five patients with a median follow-up from diagnosis of 10.6 years (range 5-25.8 years) were evaluated. Long-term thyroid toxicities were reported in 24/45 (53%) patients at a median time of 7.5 years (range 1.2-18.2; interquartile range 3-12) from diagnosis; hypothyroidism was the most common toxicity (12/24, 50% of patients). The probability of being free from thyroid toxicity at 10 years was 62% (CI: 44-75%). Analyzing children's exposure to different treatments, the probability was 0% in patients who have undergone molecular radiotherapy and 72% (CI: 53-85%) in those who did not (p < 0.001); 30% (CI: 6-59%) in those who received immunotherapy and 78% (CI: 65-90%) in those who did not (p = 0.008); 37% (CI: 12-64%) in patients treated with tandem MAT and 71% (CI: 49-85%) in children who underwent single MAT (p = 0.016); and 86% in patients who did not receive Busulfan (CI: 39-98%) and 55% (CI: 35-71%) in those who did receive Busulfan (p = 0.002). Patients undergoing immunotherapy, 131I-meta-iodobenzylguanidine therapy or Busulfan experienced thyroid toxicity significantly earlier than those who did not (p = 0.047). CONCLUSIONS: The high cumulative treatment burden in this population results in a substantial risk of thyroid toxicity, even many years after therapy. Therefore, long-term endocrine follow-up should be considered also during adulthood.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Deodati A, Fabozzi F, Mirra G, et al. Long-Term Thyroid Toxicity Burden in Children Who Received Treatment for High-Risk Neuroblastoma. Thyroid. 2026. PMID: 41735800. doi:10.1177/10507256261425684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。